Promethazine Codeine Cough Syrup: Clinical Guide to Prescription Strength Cough Suppressant

Promethazine codeine cough syrup is an FDA-approved prescription medication containing promethazine hydrochloride and codeine phosphate. It combines a sedating antihistamine with an opioid cough suppressant to treat selected severe coughs in patients aged 12 years and older. Because promethazine codeine cough syrup carries FDA Boxed Warnings for respiratory depression, addiction, and misuse, it must be used exactly as prescribed under active clinical supervision.

What Is Promethazine Codeine Cough Syrup?

Promethazine codeine cough syrup is a Schedule V prescription medication combining promethazine, a phenothiazine antihistamine, with codeine, an opioid cough suppressant. It is prescribed for short-term management of severe cough in appropriately selected adults and children aged 12 and older.

Because promethazine codeine cough syrup carries serious FDA Boxed Warnings for respiratory depression, addiction, and misuse, it must be used exactly as prescribed under active clinical supervision.

What Is Generic Phenergan With Codeine?

Generic Phenergan with codeine is the bioequivalent, non-brand-name formulation of the original Phenergan with Codeine oral solution. It contains the same active ingredients—promethazine hydrochloride and codeine phosphate—at identical concentrations, meets the same FDA standards for potency and sterility, and is therapeutically interchangeable with the brand product under standard prescribing conditions.

What Is the Standard Strength of Promethazine Codeine Oral Solution?

The standard formulation of promethazine codeine cough syrup contains 6.25 mg of promethazine hydrochloride and 10 mg of codeine phosphate per 5 mL of oral solution.

This fixed-ratio concentration defines the baseline therapeutic dose for all clinical prescribing decisions and is the reference standard against which all generic formulations of promethazine codeine cough syrup must demonstrate bioequivalence.

What Are the FDA Boxed Warnings for Promethazine Codeine?

The FDA Boxed Warning for promethazine codeine cough syrup covers four critical safety domains: life-threatening respiratory depression in pediatric patients, addiction and misuse as a Schedule V opioid-containing product, dangerous CNS depression when combined with alcohol or other central nervous system depressants, and fatal morphine exposure in CYP2D6 ultra-rapid metabolizers.

These warnings represent the highest-priority safety designations in United States pharmaceutical regulation and apply to all formulations of promethazine codeine cough syrup.

Why Is Promethazine Codeine Contraindicated in Children Under 12?

Promethazine codeine cough syrup is contraindicated in children younger than 12 because some children rapidly convert codeine into morphine through CYP2D6 metabolism, dramatically increasing the risk of fatal respiratory depression.

The FDA established this contraindication following documented pediatric deaths—not as a precautionary measure, but as a regulatory response to preventable harm caused by promethazine codeine cough syrup at standard prescribed doses.

What Are Opioid Antitussives for Severe Cough?

Opioid antitussives for severe cough include codeine-containing formulations such as promethazine codeine cough syrup, hydrocodone-homatropine syrup, and—in selected palliative care contexts—low-dose oral morphine for refractory chronic cough.

Drug selection depends on cough etiology, patient age, CYP2D6 metabolizer status, concurrent medications, and individualized clinical risk-benefit assessment. Promethazine codeine cough syrup is the most commonly prescribed Schedule V opioid antitussive in outpatient settings.

What Is the Difference Between Promethazine Codeine and Benzonatate?

Promethazine codeine cough syrup combines an opioid antitussive with a sedating antihistamine, acting centrally on the medullary cough center and peripherally on H1 receptors. Benzonatate is a non-opioid local anesthetic antitussive that acts peripherally by anesthetizing pulmonary stretch receptors.

Benzonatate carries no opioid-related addiction risk but does not address the histamine-mediated components of allergic or upper respiratory cough that promethazine codeine cough syrup targets through H1 antagonism.

What Is the Difference Between Promethazine Codeine and Dextromethorphan?

Promethazine codeine cough syrup suppresses cough through opioid mu-receptor agonism combined with H1 antihistamine activity, requiring a prescription as a Schedule V controlled substance. Dextromethorphan is a non-opioid antitussive acting via NMDA receptor antagonism and sigma receptor activity, available without a prescription.

Dextromethorphan carries no opioid dependence risk but demonstrates more limited clinical efficacy than promethazine codeine cough syrup in cases of severe, refractory cough.

Can Promethazine Codeine Be Taken With Alcohol?

Alcohol should never be consumed while taking promethazine codeine cough syrup. Both active ingredients independently depress the central nervous system; combined use produces synergistic CNS depression that can cause profound sedation, respiratory depression, coma, and death.

This interaction is addressed in the FDA Boxed Warning for promethazine codeine cough syrup. Alcohol must be completely avoided throughout the entire course of therapy—not merely at the time of each dose.

Who Should NOT Take Promethazine Codeine?

Promethazine codeine cough syrup is contraindicated in the following patients:

• Children younger than 12 years
• Patients of any age who have undergone tonsillectomy or adenoidectomy
• Patients with known hypersensitivity to codeine, promethazine, or any component of promethazine codeine cough syrup
• Patients currently using or who have used MAOIs within 14 days
• Patients with significant respiratory compromise, including untreated asthma exacerbation or respiratory failure
• Patients with paralytic ileus or known gastrointestinal obstruction

Patients with obstructive sleep apnea, CYP2D6 ultra-rapid metabolizer status, active opioid use disorder, or severe hepatic or renal impairment require enhanced monitoring or alternative therapy when promethazine codeine cough syrup is being considered.

Is Promethazine Codeine Safe During Pregnancy or Breastfeeding?

Promethazine codeine cough syrup should be avoided during pregnancy unless the clinical benefit clearly outweighs fetal risk. Codeine crosses the placental barrier and has been associated with neonatal opioid withdrawal syndrome and neonatal respiratory depression when used near term.

In breastfeeding mothers who are CYP2D6 ultra-rapid metabolizers, breast milk may contain dangerously elevated morphine concentrations following promethazine codeine cough syrup use, posing fatal overdose risk to nursing infants. The FDA advises that use of promethazine codeine cough syrup during breastfeeding requires explicit clinical justification and close infant monitoring.

When Should You Call 911 for Promethazine Codeine?

Call 911 immediately if a patient taking promethazine codeine cough syrup experiences any of the following:

• Breathing that is slow, shallow, or has stopped
• Blue, gray, or pale discoloration of lips, fingernails, or skin
• Unresponsiveness or inability to be awakened
• Seizure activity
• Loss of consciousness
• Suspected overdose from any cause

Administer naloxone if available while awaiting emergency services. Naloxone reverses the opioid component of promethazine codeine cough syrup—it does not reverse promethazine’s contribution to CNS depression. Multiple naloxone doses and extended clinical observation may be required.

Promethazine Codeine Cough Syrup at a Glance

Promethazine codeine cough syrup is a prescription medication containing promethazine hydrochloride and codeine phosphate, used for short-term treatment of severe cough in adults and children 12 and older when clinically appropriate. It suppresses the medullary cough reflex while reducing histamine-mediated symptoms through H1 receptor antagonism.

Promethazine codeine cough syrup carries FDA Boxed Warnings for addiction, misuse, life-threatening respiratory depression, and dangerous interactions with alcohol and other CNS depressants. Safe use requires careful patient selection, CYP2D6 awareness, strict adherence to prescribed dosing, and prompt clinical evaluation if serious adverse effects occur.

Key Clinical Facts: Promethazine Codeine Cough Syrup

Key Takeaways: What Clinicians and Patients Should Know

• Promethazine codeine cough syrup is a Schedule V controlled substance—its lower scheduling reflects abuse potential relative to other opioids, not a finding that clinical risk is minimal
• The standard formulation of promethazine codeine cough syrup at 6.25/10 mg per 5mL is the reference concentration for all dosing decisions and generic bioequivalence standards
• CYP2D6 ultra-rapid metabolizers face disproportionate morphine exposure at standard doses of promethazine codeine cough syrup—a pharmacogenomic risk that cannot be identified at the point of prescribing without genetic testing
• The FDA contraindication for promethazine codeine cough syrup in children under 12 was established in response to documented pediatric fatalities, not as a theoretical precaution
• Promethazine codeine cough syrup must never be used concurrently with alcohol, benzodiazepines, other opioids, or CNS depressants without explicit clinical justification and enhanced monitoring
• Short-term prescribing for a defined clinical indication is the evidence-based standard; open-ended prescriptions of promethazine codeine cough syrup are clinically indefensible
• Naloxone access should be discussed with every patient receiving promethazine codeine cough syrup or any opioid-containing antitussive

Why Promethazine Codeine Cough Syrup Demands Precise Clinical Judgment

Promethazine codeine cough syrup occupies a deceptively complex position in the prescription drug landscape. Its Schedule V classification—the lowest tier of DEA controlled substance scheduling—can create a misleading impression of minimal clinical risk.

In pharmacological reality, promethazine codeine cough syrup contains an opioid with documented addiction and respiratory depression potential, combined with a sedating phenothiazine antihistamine that amplifies CNS depression through an entirely independent receptor pathway. The result is a drug combination that is more pharmacologically consequential than its scheduling tier suggests.

Promethazine codeine cough syrup produces clinically meaningful suppression of severe cough when non-opioid alternatives have failed. It also carries a drug interaction profile that includes synergistic respiratory depression, a pediatric contraindication history written in documented fatalities, and a recreational misuse pattern—”lean” or “purple drank”—that places promethazine codeine cough syrup among the most culturally visible Schedule V agents in current clinical practice.

The challenge for clinicians, patients, and pharmacists is not simply recognizing that promethazine codeine cough syrup requires caution. It is understanding precisely why the caution is necessary at the pharmacological level—CYP2D6 genetic variability, synergistic CNS depression, the narrow therapeutic margin between antitussive dosing and respiratory compromise—and applying that understanding to every prescribing and dispensing decision involving promethazine codeine cough syrup.

This guide addresses the mechanism of action, pharmacokinetics, approved indications, dosing standards, drug interactions, side effect monitoring, and regulatory framework that define responsible use of promethazine codeine cough syrup. It is written for clinicians navigating complex cough presentations, patients seeking informed understanding of their prescription, and healthcare decision-makers evaluating the evidence base for opioid antitussive therapy.

What Is Promethazine Codeine Cough Syrup?

Promethazine codeine cough syrup is a combination prescription oral solution containing two pharmacologically distinct active agents: promethazine hydrochloride, a first-generation phenothiazine antihistamine with sedative and antiemetic properties, and codeine phosphate, a naturally occurring opioid alkaloid derived from morphine with antitussive and mild analgesic activity.

The standard formulation of promethazine codeine cough syrup—6.25/10 mg per 5mL—delivers both agents at concentrations calibrated for short-term antitussive use in patients 12 years and older. The solution must be administered using a calibrated measuring device. Household spoons introduce unacceptable dosing variability and must not be used when administering promethazine codeine cough syrup.

As a DEA Schedule V controlled substance, promethazine codeine cough syrup has recognized medical utility alongside lower—but real—abuse potential relative to Schedule II through IV opioids. Its legal manufacture, distribution, and prescribing are federally regulated. In many states, additional Prescription Drug Monitoring Program (PDMP) requirements apply to promethazine codeine cough syrup even under Schedule V.

The brand-name formulation Phenergan with Codeine is no longer commercially available in the United States. Multiple FDA-approved generic promethazine with codeine manufacturers produce bioequivalent oral solutions that must meet the same regulatory standards for identity, concentration, purity, and sterility as the reference promethazine codeine cough syrup product.

Clinical bottom line: The Schedule V designation does not minimize the clinical risk of promethazine codeine cough syrup. This medication contains an opioid capable of producing respiratory depression, physical dependence, and addiction. Every prescription for promethazine codeine cough syrup requires individualized risk assessment, patient education, and a defined plan for short-term, monitored use.

Promethazine Codeine Cough Syrup Uses and Clinical Indications

FDA-Approved Indication

According to FDA prescribing information, promethazine codeine cough syrup is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold in patients aged 12 years and older.

This indication is narrow by design. The regulatory language specifies:

• Temporary relief—promethazine codeine cough syrup is not approved for chronic or maintenance antitussive therapy
• Cough and upper respiratory symptoms—promethazine codeine cough syrup is not a first-line treatment for lower respiratory disease, asthma, or COPD exacerbation
• Patients 12 years and older—with absolute contraindication in younger children and post-surgical tonsillectomy or adenoidectomy patients of any age

Appropriate Clinical Contexts

Upper respiratory infections with severe cough: The highest-evidence use case for promethazine codeine cough syrup. It provides short-term suppression of severe, functionally disruptive cough during the acute phase of viral upper respiratory illness when non-opioid alternatives have been tried and found insufficient.

Allergic cough with prominent histaminergic component: Promethazine’s H1 receptor antagonism addresses the histamine-mediated component of allergic cough simultaneously with codeine’s central antitussive effect. This dual mechanism provides a pharmacological rationale for promethazine codeine cough syrup that neither agent alone can fully replicate.

Post-infectious cough: Persistent cough following resolved respiratory infection may respond to short-term promethazine codeine cough syrup when other agents have failed. Clinical reassessment is essential before attributing ongoing cough to post-infectious hypersensitivity.

Prescription cough syrup for severe bronchitis: A common clinical context for promethazine codeine cough syrup. Prescription of promethazine codeine cough syrup for severe bronchitis requires individualized clinical judgment, documented rationale, and scheduled reassessment. Current CHEST guidelines recommend against routinely prescribing opioid antitussives for uncomplicated acute bronchitis—a position that reflects the limited evidence base rather than a prohibition on individualized clinical judgment.

When Promethazine Codeine Cough Syrup Is Not Appropriate

• Children under 12 years of age—absolute FDA contraindication for promethazine codeine cough syrup
• Post-tonsillectomy or adenoidectomy patients of any age—FDA contraindication based on documented overdose deaths
• Patients with significant respiratory compromise, including untreated asthma or COPD exacerbation
• Patients with known or suspected obstructive sleep apnea—opioid respiratory depression risk from promethazine codeine cough syrup is substantially elevated
• Patients with active opioid use disorder without concurrent addiction medicine involvement
• Cough of unknown etiology that has not been clinically evaluated—promethazine codeine cough syrup suppression of an undiagnosed serious cough represents a diagnostic delay risk

Clinical Decision Framework: When to Consider Promethazine Codeine Cough Syrup

Promethazine and Codeine Age Restrictions: The Pediatric Contraindication

The FDA contraindication of promethazine codeine cough syrup in children under 12 is not a precautionary recommendation. It is a regulatory response to documented pediatric deaths.

Multiple case reports documented fatal and near-fatal respiratory depression in children who received promethazine codeine cough syrup and other codeine-containing medications at standard prescribed doses—particularly those who were CYP2D6 ultra-rapid metabolizers. In 2012, the FDA issued a Drug Safety Communication. In 2013, the FDA strengthened its warning to a contraindication for children under 12 for all codeine-containing products including promethazine codeine cough syrup, subsequently extended to include post-tonsillectomy and adenoidectomy patients regardless of age.

CYP2D6 Ultra-Rapid Metabolism: The Pediatric Risk Mechanism

The mechanism underlying pediatric fatalities associated with promethazine codeine cough syrup is pharmacogenomic. Codeine is a prodrug requiring conversion to morphine via CYP2D6 to produce antitussive and analgesic effect.

In patients carrying CYP2D6 gene duplications—ultra-rapid metabolizers—this conversion occurs at an accelerated rate, producing morphine plasma concentrations several times higher than those achieved in normal metabolizers receiving identical doses of promethazine codeine cough syrup. Standard antitussive doses may produce morphine concentrations sufficient to cause respiratory arrest.

This risk cannot be identified at the point of prescribing promethazine codeine cough syrup without pharmacogenomic testing. CYP2D6 ultra-rapid metabolizer status is present in approximately 1 to 28 percent of individuals depending on ethnic background—with highest prevalence in North African, Ethiopian, and Middle Eastern populations.

Ages 12 to 18: Caution, Not Clearance

The FDA contraindication applies to children under 12. Adolescents aged 12 to 18 are not categorically excluded from receiving promethazine codeine cough syrup—but they are not exempt from CYP2D6 metabolizer risk.

Clinical guidance from multiple professional organizations recommends that promethazine codeine cough syrup be used with particular caution in adolescents, at the lowest effective dose for the shortest possible duration, with explicit caregiver education regarding respiratory depression warning signs.

Expert take: The pediatric contraindication for promethazine codeine cough syrup is one of the clearest examples in modern pharmacology of a pharmacogenomic risk identified only after preventable deaths. Every prescription for promethazine codeine cough syrup—regardless of patient age—carries this pharmacogenomic dimension. A CYP2D6 ultra-rapid metabolizer prevalence of 1 to 28 percent is too clinically significant to treat as a background statistical consideration, and clinical vigilance must reflect that reality at every encounter.

Promethazine Codeine Mechanism of Action: Dual Pharmacology

Codeine: Central Opioid Antitussive

Codeine is a naturally occurring opium alkaloid that functions primarily as a prodrug. Following oral administration of promethazine codeine cough syrup, hepatic CYP2D6 converts approximately 5 to 10 percent of absorbed codeine to morphine—the pharmacologically active metabolite primarily responsible for antitussive and analgesic effects.

Morphine, and codeine itself to a lesser degree, binds to mu-opioid receptors in the medullary cough center, suppressing the cough reflex by elevating the threshold for cough initiation. Secondary mu-opioid receptor activity at spinal and supraspinal levels contributes mild analgesic effect that may provide additional symptomatic benefit in patients with cough-associated chest wall discomfort following doses of promethazine codeine cough syrup.

Promethazine: H1 Antagonism and Phenothiazine Sedation

Promethazine hydrochloride is a first-generation phenothiazine derivative with potent H1 histamine receptor antagonism, moderate anticholinergic activity, and significant dopamine receptor blockade. Its contributions to promethazine codeine cough syrup include:

• Antitussive synergy: H1 receptor antagonism reduces histamine-mediated bronchospasm and upper airway irritation contributing to cough
• Antiemetic effect: Dopamine receptor blockade in the chemoreceptor trigger zone reduces nausea—clinically relevant given codeine’s emetogenic properties at initiation of promethazine codeine cough syrup
• Sedation: Both H1 and dopamine receptor blockade produce CNS sedation that reinforces codeine’s antitussive effect while amplifying respiratory depression risk

The Synergistic CNS Depression Problem

The most clinically consequential pharmacological feature of promethazine codeine cough syrup is CNS depression synergy. Both agents independently produce sedation through distinct receptor mechanisms.

Combined in promethazine codeine cough syrup, their CNS depressant effects are not simply additive—they are potentially synergistic, particularly when a patient introduces a third CNS depressant such as alcohol, a benzodiazepine, or another opioid. This synergy is the pharmacological basis for the FDA Boxed Warning on alcohol and CNS depressant interactions with promethazine codeine cough syrup.

Expert take: Promethazine codeine cough syrup is not simply codeine plus an antihistamine. It is a combination in which two mechanistically distinct CNS depressants are co-administered at therapeutic doses. The clinical safety margin for adding a third CNS depressant while taking promethazine codeine cough syrup—even a single alcoholic drink—is narrower than many patients and some clinicians appreciate. The FDA Boxed Warning exists because the interaction is pharmacologically inevitable and clinically documented.

Promethazine Codeine 6.25/10 mg per 5mL: Dosing Standards

Standard Formulation

The promethazine codeine cough syrup 6.25/10 mg per 5mL oral solution is the reference formulation for all prescribing decisions. Each 5mL dose of promethazine codeine cough syrup delivers:

• 6.25 mg promethazine hydrochloride
• 10 mg codeine phosphate

This fixed-ratio combination cannot be titrated independently. Adjusting the dose of promethazine codeine cough syrup requires changing the volume administered, which simultaneously alters exposure to both active ingredients.

Adult Dosing

Standard adult dose: 5mL of promethazine codeine cough syrup measured with a calibrated oral dosing syringe, every 4 to 6 hours as needed.

Maximum daily dose: Total codeine exposure from promethazine codeine cough syrup must be considered alongside any other codeine or opioid-containing medications the patient is receiving. Evidence-based prescribing standards support the lowest effective dose for the shortest necessary duration.

Duration of therapy: Promethazine codeine cough syrup is a short-term antitussive. Prescriptions extending beyond 5 to 7 days require documented clinical reassessment. Open-ended refills of promethazine codeine cough syrup are not clinically appropriate.

Adolescent Dosing (Ages 12 to 18)

Adolescent patients should receive the lowest dose of promethazine codeine cough syrup that achieves symptom control. Prescribers should document the rationale for initiating promethazine codeine cough syrup in this age group and ensure caregivers receive education regarding respiratory depression warning signs before the first dose is dispensed.

Dosing Precision: Why Calibrated Measuring Devices Matter

Promethazine codeine cough syrup must be measured using a calibrated oral dosing syringe or medication cup. Household spoons may deliver anywhere from 2.5mL to 7.5mL—a three-fold dosing error at the extremes.

For a medication with a defined therapeutic window and documented overdose risk, dosing imprecision with promethazine codeine cough syrup is a patient safety failure. Every prescription should include explicit instruction to use only a calibrated measuring device, and pharmacists should routinely dispense one alongside promethazine codeine cough syrup as standard practice.

How Long Does Promethazine Codeine Stay in Your System?

Understanding how long promethazine codeine cough syrup stays in your system requires separately addressing each active ingredient. Promethazine and codeine have substantially different pharmacokinetic profiles that produce clinically distinct duration-of-effect and detection windows.

Codeine Pharmacokinetics

• Onset of action: 15 to 30 minutes after oral administration of promethazine codeine cough syrup
• Peak plasma concentration: Approximately 1 hour
• Duration of antitussive effect: 4 to 6 hours per dose of promethazine codeine cough syrup
• Elimination half-life: Approximately 2.5 to 4 hours; active metabolite morphine has a half-life of 2 to 4 hours
• Time to substantial clearance: Approximately 12 to 20 hours under normal hepatic and renal function

Promethazine Pharmacokinetics

• Onset of action: 20 to 30 minutes after oral administration of promethazine codeine cough syrup
• Duration of sedative effect: 4 to 6 hours; sedation from promethazine codeine cough syrup may persist substantially longer at clinical doses
• Elimination half-life: Approximately 10 to 19 hours—substantially longer than codeine
• Key clinical implication: Promethazine’s extended half-life means sedative effects from promethazine codeine cough syrup persist well beyond codeine’s antitussive duration, particularly after multiple doses

Drug Testing Detection Windows

Factors Influencing Clearance

• CYP2D6 genotype: Ultra-rapid metabolizers convert codeine from promethazine codeine cough syrup to morphine rapidly; poor metabolizers produce minimal morphine with prolonged codeine accumulation and reduced antitussive effect
• Hepatic function: Impaired CYP2D6 and CYP3A4 activity prolongs codeine half-life following promethazine codeine cough syrup dosing and alters metabolite ratios
• Renal function: Morphine glucuronide metabolites accumulate in renal impairment, potentially extending opioid effect beyond expected duration
• Age: Elderly patients demonstrate reduced clearance; promethazine’s anticholinergic and sedative effects from promethazine codeine cough syrup are disproportionately amplified
• Concurrent medications: CYP2D6 and CYP3A4 inhibitors or inducers alter both codeine metabolism and morphine exposure from promethazine codeine cough syrup in clinically significant ways

Promethazine Codeine Side Effects: Clinical Monitoring Framework

Common Side Effects

Promethazine codeine side effects reflect the combined pharmacological activity of both agents in promethazine codeine cough syrup—opioid receptor agonism, H1 receptor antagonism, anticholinergic activity, and dopamine receptor blockade operating simultaneously.

Central nervous system:

• Sedation and drowsiness—the most consistently reported adverse effect of promethazine codeine cough syrup, driven independently by both ingredients with synergistic amplification when combined
• Dizziness and impaired coordination
• Cognitive dulling and slowed psychomotor response
• Confusion, particularly in elderly patients and those with baseline cognitive impairment receiving promethazine codeine cough syrup

Gastrointestinal:

• Nausea and vomiting—codeine’s stimulation of the chemoreceptor trigger zone at initiation of promethazine codeine cough syrup may cause nausea before promethazine’s antiemetic effect is established
• Constipation (opioid-induced constipation)—does not resolve with continued promethazine codeine cough syrup use; stimulant laxative prophylaxis is appropriate for patients using the medication beyond 2 to 3 days
• Dry mouth—driven by anticholinergic activity of promethazine
• Delayed gastric emptying

Other:

• Blurred vision (anticholinergic)
• Urinary retention (anticholinergic), particularly in older male patients with benign prostatic hyperplasia taking promethazine codeine cough syrup
• Pruritus (opioid histamine release)
• Photosensitivity—promethazine in promethazine codeine cough syrup increases UV skin sensitivity throughout the course of therapy

Serious Adverse Effects Requiring Immediate Clinical Response

Respiratory depression: The most dangerous acute complication of promethazine codeine cough syrup therapy. Clinical warning signs include respiratory rate below 12 breaths per minute, shallow or irregular breathing, extreme drowsiness or unresponsiveness, and cyanosis of the lips or fingernails.

Suspected respiratory depression from promethazine codeine cough syrup requires immediate emergency services activation and naloxone administration if available. Naloxone reverses only the opioid component—promethazine’s contribution to CNS depression in promethazine codeine cough syrup does not respond to opioid antagonist therapy.

Neuroleptic Malignant Syndrome (NMS): A rare but potentially fatal reaction associated with promethazine’s dopamine receptor antagonism in promethazine codeine cough syrup. NMS presents with hyperthermia, muscular rigidity, altered consciousness, and autonomic instability. Immediate discontinuation of promethazine codeine cough syrup and emergency evaluation are required.

QT prolongation: Promethazine in promethazine codeine cough syrup has documented QT-prolonging potential. Patients with baseline QT prolongation, electrolyte abnormalities, or concurrent QT-prolonging agents face elevated risk of potentially fatal cardiac arrhythmia when taking promethazine codeine cough syrup.

Dystonic reactions: Dopamine receptor blockade by promethazine in promethazine codeine cough syrup can produce acute dystonia—particularly in younger patients and those receiving higher doses.

Opioid Antitussive Drug Interactions: Clinical Risk Management

CYP2D6 Interactions: The Most Pharmacogenomically Significant Category

CYP3A4 Interactions

CNS Depressant Combinations: Highest-Risk Interactions

MAOIs: Absolute Contraindication

Concurrent use of promethazine codeine cough syrup with monoamine oxidase inhibitors or within 14 days of MAOI discontinuation is absolutely contraindicated. The combination risks serotonin syndrome, unpredictable opioid potentiation, and potentially fatal autonomic instability.

Clinical requirement: Complete medication reconciliation—including prescription medications, over-the-counter products, herbal supplements, and alcohol—must be completed before dispensing promethazine codeine cough syrup at every prescription encounter.

Driving, Operating Machinery, and Cognitive Impairment

Promethazine codeine cough syrup impairs cognitive function, reaction time, and psychomotor performance through two independent pharmacological mechanisms—opioid CNS depression and phenothiazine sedation.

Patients must not drive or operate dangerous machinery while taking promethazine codeine cough syrup. This restriction applies:

• From the first dose of promethazine codeine cough syrup, not only during initial therapy
• Throughout the full course of treatment, not only when sedation is subjectively felt
• Following any dose of promethazine codeine cough syrup, including evening doses that may produce residual impairment the following morning given promethazine’s 10 to 19 hour half-life

Patients should be counseled that subjective feelings of alertness may not accurately reflect actual psychomotor function while taking promethazine codeine cough syrup—a discrepancy documented in opioid and antihistamine pharmacodynamic research.

Promethazine With Codeine Generic Manufacturers: Regulatory Standards

Bioequivalence Requirements

FDA-approved promethazine with codeine generic manufacturers must demonstrate bioequivalence through pharmacokinetic studies confirming that the generic formulation’s peak plasma concentration (Cmax) and total drug exposure (AUC) for both active ingredients fall within the FDA’s 80–125% acceptance criteria relative to the reference listed drug.

This standard ensures that generic promethazine codeine cough syrup delivers therapeutically equivalent exposure under normal use conditions.

What Generic Equivalence Does and Does Not Mean

Generic bioequivalence confirms equivalent pharmacokinetic exposure to both active ingredients in promethazine codeine cough syrup. It does not guarantee identical inactive ingredient composition, taste, color, viscosity, preservative systems, or shelf stability.

For most patients, these differences in generic promethazine codeine cough syrup formulations are clinically irrelevant. For patients with known hypersensitivity to specific excipients, formulation-specific considerations may warrant clinical attention.

Practical guidance: Clinicians and pharmacists should verify that any dispensed generic promethazine codeine cough syrup product holds FDA approval and is listed in the Orange Book with an AB therapeutic equivalence rating. Products without AB ratings have not demonstrated bioequivalence and should not be substituted without clinical review.

Antitussive Comparison: Promethazine Codeine vs Available Alternatives

Prescription Cough Syrup for Severe Bronchitis: Clinical Evidence and Prescribing Context

The Evidentiary Landscape

The clinical evidence supporting promethazine codeine cough syrup and other opioid antitussive therapies for acute bronchitis is more limited than historical prescribing frequency suggests.

A 2014 Cochrane systematic review found insufficient high-quality evidence to recommend any specific antitussive, including the codeine component of promethazine codeine cough syrup, over placebo in acute adult cough. The 2016 CHEST guidelines recommended against routinely prescribing opioid antitussives such as promethazine codeine cough syrup for uncomplicated acute bronchitis, citing the limited evidence base and significant risk profile.

When Prescribing May Be Clinically Justified

Despite limited population-level evidence, clinical situations exist in which promethazine codeine cough syrup represents a reasoned prescribing decision:

• Severe, functionally disruptive cough that has not responded to non-opioid antitussives
• Cough-induced complications such as syncope, vomiting, rib fractures, or sleep deprivation sufficient to warrant short-term promethazine codeine cough syrup
• Patients with documented hypersensitivity or contraindication to non-opioid alternatives
• Terminal or palliative care settings where quality of life outweighs concerns about promethazine codeine cough syrup dependence risk

In all cases, the prescribing rationale for promethazine codeine cough syrup must be documented, the duration minimized, and formal reassessment scheduled.

Patient Selection, Contraindications, and Risk Stratification

Appropriate Candidates for Promethazine Codeine Cough Syrup

Promethazine codeine cough syrup is clinically appropriate for patients who:

• Are 12 years of age or older with no history of post-tonsillectomy or adenoidectomy
• Present with severe cough producing functional impairment that has not responded to non-opioid antitussive therapy
• Have no contraindications to opioid or phenothiazine components of promethazine codeine cough syrup
• Have undergone complete medication reconciliation confirming no high-risk drug interactions
• Can be educated regarding dosing precision, drug interactions, respiratory depression warning signs, and safe storage of promethazine codeine cough syrup
• Will be monitored during therapy with a defined reassessment date

Populations Requiring Enhanced Monitoring or Alternative Therapy

Elderly patients: Reduced hepatic and renal clearance prolongs both active ingredients of promethazine codeine cough syrup. Promethazine’s anticholinergic effects—urinary retention, constipation, confusion—are amplified in older adults. The American Geriatrics Society Beers Criteria lists first-generation antihistamines including promethazine as medications to avoid in patients 65 and older, which directly applies to prescribing decisions involving promethazine codeine cough syrup.

Patients with sleep-disordered breathing: Obstructive sleep apnea significantly amplifies opioid respiratory depression risk from promethazine codeine cough syrup. If prescribed in this population, use must be at the lowest possible dose for the shortest possible duration.

Patients with CYP2D6 ultra-rapid metabolizer status: These patients face disproportionate morphine exposure at standard doses of promethazine codeine cough syrup. If pharmacogenomic testing has identified ultra-rapid metabolizer status, promethazine codeine cough syrup requires exceptional caution or avoidance.

Patients with history of substance use disorder: Require individualized risk assessment and, where appropriate, addiction medicine consultation before promethazine codeine cough syrup is prescribed.

Safe Storage, Missed Dose, and Disposal

Safe Storage

Promethazine codeine cough syrup must be stored securely to prevent access by children, adolescents, and individuals for whom it was not prescribed. Storage requirements include:

• Locked cabinet or secure location inaccessible to all household members
• Original prescription container with child-resistant cap
• Room temperature storage away from heat, light, and moisture
• Never transferred to unlabeled containers

Missed Dose Guidance

If a scheduled dose of promethazine codeine cough syrup is missed, the patient should take the dose as soon as remembered—unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

Patients must never double a dose of promethazine codeine cough syrup. Patients should be explicitly counseled against taking extra doses to compensate for perceived inadequate symptom control.

Safe Disposal

Unused promethazine codeine cough syrup must be disposed of promptly using:

• DEA-authorized drug take-back programs
• FDA-approved drug deactivation pouches if take-back is unavailable
• Mixing with unpalatable substances in a sealed container before household trash disposal as a last resort

Patients should verify current FDA guidance before flushing promethazine codeine cough syrup, as flushing is recommended only for specific agents on the FDA flush list.

Opioid Safety Framework: Regulatory Standards and Patient Education

FDA Boxed Warning: Complete Summary

Controlled Substance Prescribing Standards

As a DEA Schedule V controlled substance, promethazine codeine cough syrup is subject to:

• Prescription requirements varying by state law
• PDMP consultation requirements in most states before dispensing promethazine codeine cough syrup
• Dispensing quantity limits in some jurisdictions
• Documentation requirements for refills where state law permits Schedule V refills of promethazine codeine cough syrup

Patient Education: Non-Negotiable Minimum

Every patient receiving a promethazine codeine cough syrup prescription should receive explicit, documented education on:

1. Correct dose measurement using a calibrated oral dosing syringe—never a household spoon
2. Complete avoidance of alcohol throughout the entire course of promethazine codeine cough syrup therapy
3. Prohibition on driving or operating machinery while taking promethazine codeine cough syrup
4. Recognition of respiratory depression warning signs and when to call 911
5. Safe storage of promethazine codeine cough syrup to prevent access by children and unauthorized individuals
6. Proper disposal of unused promethazine codeine cough syrup
7. The importance of taking promethazine codeine cough syrup exactly as prescribed

Key Statistics: Prevalence, Risk, and Public Health Context

Understanding the public health dimensions of promethazine codeine cough syrup use places individual prescribing decisions in appropriate epidemiological context.

• CYP2D6 ultra-rapid metabolizer prevalence: Approximately 1 to 28 percent of individuals depending on ethnic background—a range that makes pharmacogenomic risk from promethazine codeine cough syrup clinically significant across all patient populations
• Recreational misuse: The National Survey on Drug Use and Health (NSDUH) documents consistent misuse of promethazine codeine cough syrup among adolescents and young adults; the “lean” or “purple drank” phenomenon has been linked to multiple overdose fatalities
• Pediatric codeine fatalities: The FDA’s 2013 Drug Safety Communication cited multiple cases of death and life-threatening respiratory depression in children who received codeine-containing products including formulations equivalent to promethazine codeine cough syrup
• Opioid-benzodiazepine mortality: CDC data document a four-fold increase in overdose mortality when opioids are combined with benzodiazepines—a risk that applies to promethazine codeine cough syrup as a Schedule V opioid-containing product

Evidence Summary: What the Research Demonstrates

Current Evidence Base

Antitussive efficacy:
The evidence base for promethazine codeine cough syrup and other opioid antitussives in acute cough demonstrates modest efficacy over placebo in selected adult populations. A 2014 Cochrane review found limited high-quality evidence for any antitussive in acute adult cough—underscoring the importance of reserving promethazine codeine cough syrup for cases where severity clearly justifies the associated risk.

CYP2D6 pharmacogenomics:
Pharmacogenomic research has established that CYP2D6 ultra-rapid metabolizer status is present in 1 to 28 percent of individuals. This prevalence, combined with the inability to identify ultra-rapid metabolizer status at the point of prescribing promethazine codeine cough syrup without genetic testing, is the pharmacological foundation for the FDA’s pediatric contraindication.

Recreational misuse and overdose mortality:
Epidemiological data from the NSDUH and FDA adverse event reports document significant recreational misuse of promethazine codeine cough syrup, particularly among adolescents. The “lean” or “purple drank” phenomenon—involving large-volume consumption of promethazine codeine cough syrup—has been linked to multiple overdose deaths.

Evidence Quality Summary

Frequently Asked Questions: Promethazine Codeine Cough Syrup

What is promethazine codeine cough syrup?

Promethazine codeine cough syrup is an FDA-approved prescription combination oral solution containing promethazine hydrochloride and codeine phosphate. Promethazine codeine cough syrup is indicated for short-term treatment of severe cough in appropriately selected patients aged 12 and older and is classified as a DEA Schedule V controlled substance requiring physician authorization and active clinical monitoring.

What are the most common side effects of promethazine codeine?

Common promethazine codeine side effects include sedation, dizziness, dry mouth, constipation, nausea, blurred vision, and urinary retention. Sedation is the most consistently reported adverse effect of promethazine codeine cough syrup. Constipation does not resolve with continued use and requires proactive stimulant laxative management in patients using promethazine codeine cough syrup beyond two to three days.

Why is promethazine codeine not recommended for children under 12?

The FDA contraindicated promethazine codeine cough syrup in children under 12 following documented cases of fatal respiratory depression in CYP2D6 ultra-rapid metabolizers. In these individuals, standard doses of promethazine codeine cough syrup produce morphine plasma concentrations sufficient to cause respiratory arrest—a risk that cannot be identified at the point of prescribing without pharmacogenomic testing.

Can promethazine codeine be taken with alcohol?

No. Alcohol must be completely avoided during promethazine codeine cough syrup therapy. Both active ingredients independently produce CNS depression; alcohol produces a third, synergistic depressant effect that dramatically amplifies the risk of respiratory depression, coma, and death when combined with promethazine codeine cough syrup.

How long does promethazine codeine stay in the body?

Codeine from promethazine codeine cough syrup has an elimination half-life of approximately 2.5 to 4 hours, with substantial clearance within 12 to 20 hours. Promethazine has a half-life of 10 to 19 hours—meaning sedative effects from promethazine codeine cough syrup persist well beyond codeine’s antitussive duration. Urine drug testing may detect both agents for 2 to 3 days following the last dose of promethazine codeine cough syrup.

What is the standard strength of promethazine codeine oral solution?

The standard formulation of promethazine codeine cough syrup contains 6.25 mg of promethazine hydrochloride and 10 mg of codeine phosphate per 5 mL. This concentration is the reference standard for all clinical dosing decisions and the benchmark against which all generic formulations of promethazine codeine cough syrup must demonstrate bioequivalence.

What medications interact with promethazine codeine?

Clinically significant interactions with promethazine codeine cough syrup include alcohol (Boxed Warning; contraindicated), benzodiazepines (Boxed Warning), other opioids, gabapentinoids, muscle relaxants, CYP2D6 inhibitors such as fluoxetine and paroxetine, CYP3A4 inhibitors such as ketoconazole and clarithromycin, and MAOIs (absolutely contraindicated). Complete medication reconciliation is required before dispensing promethazine codeine cough syrup.

What are the alternatives to promethazine codeine for cough?

Non-opioid alternatives to promethazine codeine cough syrup include benzonatate, dextromethorphan, and guaifenesin. Opioid alternatives include hydrocodone-homatropine for patients requiring opioid antitussive therapy who cannot receive codeine-containing products. Drug selection should be based on cough etiology, patient age, metabolizer status, concurrent medications, and individualized risk-benefit assessment by a qualified clinician.

Clinical Pearls: Key Takeaways for Practice

Clinical Pearl 1: The Schedule V designation of promethazine codeine cough syrup does not indicate minimal clinical risk. This medication contains two pharmacologically active CNS depressants, one of which is an opioid with documented addiction, respiratory depression, and dependence potential. The scheduling reflects abuse liability relative to other controlled substances—not a determination that promethazine codeine cough syrup is safe for unsupervised or open-ended use.

Clinical Pearl 2: CYP2D6 ultra-rapid metabolizer prevalence ranges from 1 to 28 percent depending on ethnic background. A clinically meaningful proportion of patients prescribed standard doses of promethazine codeine cough syrup face pharmacokinetically predictable but clinically invisible risk of excessive morphine exposure. This is the reason the pediatric contraindication exists—and the reason vigilance must extend to all patients receiving promethazine codeine cough syrup, regardless of age.

Clinical Pearl 3: Promethazine’s half-life of 10 to 19 hours substantially exceeds codeine’s antitussive duration of 4 to 6 hours. Patients taking multiple daily doses of promethazine codeine cough syrup accumulate promethazine plasma concentrations well above single-dose levels. The sedative and anticholinergic burden at steady state is clinically higher than single-dose pharmacokinetics suggest—particularly relevant in elderly patients receiving promethazine codeine cough syrup.

Clinical Pearl 4: The recreational misuse pattern associated with promethazine codeine cough syrup—large-volume consumption mixed with soft drinks—is a documented cause of overdose deaths involving a legal Schedule V prescription product. Awareness of this pattern should inform prescribing decisions, dispensing quantity limits, and patient education whenever promethazine codeine cough syrup is prescribed to adolescent patients.

Clinical Pearl 5: Dosing precision is a patient safety requirement for promethazine codeine cough syrup. Household spoons may deliver up to three times the intended dose volume. Every prescription for promethazine codeine cough syrup should include explicit instruction to use only a calibrated oral dosing syringe, dispensed by the pharmacist as standard practice alongside the medication.

References

• FDA Prescribing Information: Promethazine Hydrochloride and Codeine Phosphate Oral Solution
• FDA Drug Safety Communication: Codeine Use in Certain Children After Tonsillectomy and/or Adenoidectomy (2013)
• FDA Opioid Analgesic REMS Program
• Irwin RS, et al. Diagnosis and Management of Cough Executive Summary: CHEST Guideline and Expert Panel Report. CHEST. 2006;129(1 Suppl):1S–23S.
• Morice AH, et al. ERS Guidelines on the Diagnosis and Treatment of Chronic Cough in Adults and Children. European Respiratory Journal. 2020;55(1):1901136.
• Smith SM, et al. Over-the-Counter (OTC) Medications for Acute Cough in Children and Adults in Community Settings. Cochrane Database of Systematic Reviews. 2014;(11):CD001831.
• Gasche Y, et al. Codeine Intoxication Associated with Ultrarapid CYP2D6 Metabolism. New England Journal of Medicine. 2004;351(27):2827–2831.
• National Library of Medicine: Codeine
• DEA Drug Scheduling
• FDA MedWatch Adverse Event Reporting
• CDC: Opioid Overdose Data

Conclusion: Precision Is the Clinical Standard

Promethazine codeine cough syrup delivers genuine clinical value for a defined patient population: adults and adolescents aged 12 and older with severe, functionally disruptive cough that has not responded to non-opioid antitussive therapy. When promethazine codeine cough syrup is prescribed to appropriately selected patients—with complete medication review, calibrated dosing instruction, explicit alcohol and drug interaction counseling, and a defined short-term treatment plan—it remains a pharmacologically rational and clinically effective option.

What the evidence equally demands is that this clinical value be pursued without underestimating the pharmacological complexity of promethazine codeine cough syrup. This is not simply a stronger version of an over-the-counter cough remedy. Promethazine codeine cough syrup is a Schedule V controlled substance combining two CNS depressants through distinct but synergistic mechanisms, metabolized by enzymes whose genetic variability creates clinically meaningful—and potentially fatal—differences in individual drug exposure.

The FDA Boxed Warning for promethazine codeine cough syrup was written in response to preventable deaths. The contraindication for children under 12 exists because CYP2D6 ultra-rapid metabolism is neither rare nor predictable at the point of prescribing promethazine codeine cough syrup, and because the morphine exposure it generates in susceptible individuals is not survivable at the extremes. The warning against alcohol and CNS depressants reflects a pharmacodynamic interaction that is mechanistically inevitable in patients taking promethazine codeine cough syrup—not a theoretical edge case.

Responsible prescribing of promethazine codeine cough syrup requires understanding its side effects across both active ingredients, knowing how long promethazine codeine cough syrup stays in the system across pharmacokinetically diverse patient populations, recognizing opioid antitussive drug interactions at the CYP enzyme level, applying promethazine and codeine age restrictions with regulatory precision, and maintaining the clinical discipline to prescribe promethazine codeine cough syrup for the shortest duration the clinical situation genuinely requires.

In every domain of controlled substance prescribing, clinical precision is the protection that patients depend on—and the standard to which every decision involving promethazine codeine cough syrup must be held.

This article is intended for informational purposes only and does not constitute medical advice, clinical guidance, or a recommendation for any specific treatment. Promethazine codeine cough syrup is a Schedule V controlled substance requiring physician authorization and clinical oversight. All treatment decisions should be made in consultation with a qualified, licensed healthcare professional. Content is reviewed for clinical accuracy and updated as the evidence base evolves.